The 1964 report that paved the way for Canada's medicare envisaged that after universal coverage for doctors, the next step would be prescription drugs. But that next step hasn't come.
Drug companies have a job to do and so does Health Canada. When the relationship becomes murky, the public are at risk.
Three-quarters of people with an intellectual disability receive prescribed drugs.
The collective public health of Canada, the United States and Mexico will take a hit if the new NAFTA becomes law.
Health Canada must be unbiased and it must be seen to be unbiased -- so that Canadians get the best possible value out of prescription drugs.
Alarming rise in deaths from two prescription drugs sees them reclassified as class C.
A new study reveals how many patient groups lobby for new drugs to be funded by public plans in Canada -- all while receiving funding from the companies manufacturing the drugs in question.
It takes about three years for safety problems to be identified in new drugs, newer drugs are almost always more expensive, and yet Canadian doctors still hand out hundreds of thousands of samples.
Two community pharmacists suggest a way for improving the palatability of evidence-based universal pharmacare -- for those working in health insurance, pharmacy and the pharmaceutical industry.
Buyers think you can tell the purity of a substance by looking at on an app – evidence shows they're mistaken.
Insurance companies sometimes try to cut costs by substituting less expensive drugs for a specific drug prescription. That's raising problems in many cases, and actually causing harm.
Shortages and high prices are making pharmaceuticals, often including generics, out of reach for millions of Americans.
The medication landscape is complicated and error-riddled, with very few care providers knowing all the drugs you are taking. Here's how pharmacists could be the solution.
As Canadians consider possibilities for pharmacare reform in the coming months, they should have access to the best available evidence about how it might work in our country.
The strengths of blockchain technologies could help address the weaknesses of health care systems to store and secure medical records.
Big Pharma in Canada is far behind the curve when it comes to disclosing what payments to health-care professionals are for.
The Canadian government must undertake regular analysis of the drug shortage problem, if we are ever to develop sustainable solutions.
The logic behind U.S. president Donald Trump's proposal that Canada and other countries have been “free-riding” off high prices in the United States is bizarre at best.
Current guidance is not leading to cost-effective practice.
The cost of a life-saving drug in Canada is rising by 3,000 per cent. A national pharmacare plan could bring order to this chaotic world of Canadian drug prices.